AR081552A1 - Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes - Google Patents
Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunesInfo
- Publication number
- AR081552A1 AR081552A1 ARP110101806A AR081552A1 AR 081552 A1 AR081552 A1 AR 081552A1 AR P110101806 A ARP110101806 A AR P110101806A AR 081552 A1 AR081552 A1 AR 081552A1
- Authority
- AR
- Argentina
- Prior art keywords
- fused
- nhc
- heterocycloalkane
- heteroarene
- nhr1
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 60
- 150000002390 heteroarenes Chemical class 0.000 abstract 21
- 101150009274 nhr-1 gene Proteins 0.000 abstract 21
- 150000001924 cycloalkanes Chemical class 0.000 abstract 20
- 150000001925 cycloalkenes Chemical class 0.000 abstract 19
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 16
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 16
- 229910052717 sulfur Inorganic materials 0.000 abstract 12
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 6
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 5
- 125000000565 sulfonamide group Chemical group 0.000 abstract 5
- -1 C (O) N (R1) 2 Proteins 0.000 abstract 4
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- FEIACFYXEWBKHU-UHFFFAOYSA-N (2-aminopyridin-3-yl)methanol Chemical compound NC1=NC=CC=C1CO FEIACFYXEWBKHU-UHFFFAOYSA-N 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 102220492355 2'-5'-oligoadenylate synthase 3_R30A_mutation Human genes 0.000 abstract 2
- 102220544041 60S ribosomal protein L27_R10A_mutation Human genes 0.000 abstract 2
- 102220542311 60S ribosomal protein L27_R19A_mutation Human genes 0.000 abstract 2
- 102220465933 Beta-1,3-glucuronyltransferase LARGE2_R15A_mutation Human genes 0.000 abstract 2
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 abstract 2
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 abstract 2
- 102220614548 Calmodulin-3_R23A_mutation Human genes 0.000 abstract 2
- 102220614557 Calmodulin-3_R31A_mutation Human genes 0.000 abstract 2
- 102220605451 Coilin_R36A_mutation Human genes 0.000 abstract 2
- 102220503974 Endogenous retrovirus group K member 6 Rec protein_R13A_mutation Human genes 0.000 abstract 2
- 102220503971 Endogenous retrovirus group K member 6 Rec protein_R14A_mutation Human genes 0.000 abstract 2
- 102220503970 Endogenous retrovirus group K member 6 Rec protein_R18A_mutation Human genes 0.000 abstract 2
- 102220503968 Endogenous retrovirus group K member 6 Rec protein_R20A_mutation Human genes 0.000 abstract 2
- 102220555063 Holliday junction recognition protein_R25A_mutation Human genes 0.000 abstract 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 2
- 102220595577 Major vault protein_R24A_mutation Human genes 0.000 abstract 2
- 102220507254 Rab11 family-interacting protein 1_R38K_mutation Human genes 0.000 abstract 2
- 102220500097 eIF5-mimic protein 2_R34A_mutation Human genes 0.000 abstract 2
- 102220481543 eIF5-mimic protein 2_R39A_mutation Human genes 0.000 abstract 2
- GCVFCUPRTZORNH-UHFFFAOYSA-N n,n-dimethyl-3-[4-(1,10-phenanthrolin-4-yl)butoxy]aniline;2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.CN(C)C1=CC=CC(OCCCCC=2C3=C(C4=NC=CC=C4C=C3)N=CC=2)=C1 GCVFCUPRTZORNH-UHFFFAOYSA-N 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 101100294108 Caenorhabditis elegans nhr-41 gene Proteins 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 102220030673 rs59931416 Human genes 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
- A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que inhiben la actividad de las proteínas anti-apoptóticas Bcl-2, composiciones que contienen dichos compuestos y métodos para tratar enfermedades durante las cuales se expresa la proteína anti-apoptótica Bcl-2.Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), fórmula (2), ó fórmula (3) donde A1 es N o C(A2); A2 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; B1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; D1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; E1 es H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 o C(O)OR1A; y Y1 es H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, NH2, NHR17, N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17 o NHSO2R17; G1 es R1B, OR1B, o NHR1B; donde R1B, o un sustituyente sobre R1B, está sustituido o adicionalmente sustituido con S(O)2(OH), C(O)OR50OP(O)(OH)(OH), C(O)R50OP(O)(OH)(OH), C(O)NH(R50)NH2, C(O)R50C(O)NR50; OR50P(O)(OH)(OH), OP(O)(OH)(OH), o OC(O)CH2OP(O)(OH)(OH); R1 y R1B son en forma independiente entre sí R2, R3, R4 o R5; R1A es alquilo C1-6, alquenilo C3-6 o alquinilo C3-6; R2 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R2A; R2A es cicloalcano o heterocicloalcano; R3 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R3A; R3A es cicloalcano o heterocicloalcano; R4 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R4A; R4A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R5 es alquilo, alquenilo o alquinilo, cada uno de los cuales en forma independiente no está sustituido, no está adicionalmente sustituido, está sustituido o está adicionalmente sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR1, OH, (O), C(O)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, Cl, Br o I; R6 es espiroalquilo C2-5, el cual no está sustituido o está sustituido con OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) o N(CH3)2; R6A y R6B son sustituyentes seleccionados en forma independiente entre alquilo o, junto con el N al cual están unidos, R6C; R6C es aziridin-1-ilo, azetidin-1-ilo, pirrolidin-1-ilo o piperidin-1-ilo, donde en cada uno una porción CH2 no se reemplaza o se reemplaza por O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH; R7 es R8, R9, R10 o R11; R8 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R8A; R8A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R9 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R9A; R9A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R10 es cicloalquilo C3-10 o cicloalquenilo C4-10, donde en cada uno una o dos porciones CH2 no se reemplazan o se reemplazan por sustituyentes seleccionados en forma independiente entre O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH y una o dos porciones CH no se reemplazan o se reemplazan por N, y cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R10A; R10A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R11 es alquilo, alquenilo o alquinilo, cada uno de los cuales no está sustituido o está sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R12, OR12, NHR12, N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br o I; R12 es R13, R14, R15 o R16; R13 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R13A; R13A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R14 es heteroarilo, cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R14A; R14A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R15 es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno, cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R15A; R15A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R16 es alquilo, alquenilo o alquinilo; R17 es R18, R19, R20 o R21; R18 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R18A; R18A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R19 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R19A; R19A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R20 es cicloalquilo C3-10 o cicloalquenilo C4-10, donde en cada uno una o dos porciones CH2 no se reemplazan o se reemplazan por sustituyentes seleccionados en forma independiente entre O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH y una o dos porciones CH no se reemplazan o se reemplazan por N, y cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R20A; R20A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R21 es alquilo, alquenilo o alquinilo, cada uno de los cuales no está sustituido o está sustituido con uno o dos o tres sustituyentes seleccionados en forma independiente entre R22, OR22, NHR22, N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br o I; R22 es R23, R24 o R25; R23 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R23A; R23A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R24 es heteroareno que no está fusionado o está fusionado con benceno, heteroareno o R24A; R24A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R25 es cicloalquilo C3-6 o cicloalquenilo C4-6, donde en cada uno una o dos porciones CH2 no se reemplazan o se reemplazan por sustituyentes seleccionados en forma independiente entre O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH y una o dos porciones CH no se reemplazan o se reemplazan por N, y cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R25A; R25A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R30 es cicloalquilo o cicloalquenilo, donde en cada uno una o dos porciones CH2 no se reemplazan o se reemplazan por sustituyentes seleccionados en forma independiente entre O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH y una o dos porciones CH no se reemplazan o se reemplazan por N, y cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R30A; R30A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; donde R30 está sustituido con F, CI, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(O)R37, OR37, SR37, S(O)R37, SO2R37, NHR37 o N(R32)R37; R31 y R31A son en forma independiente F, Cl, Br o alquilo o se toman juntos y son espiroalquilo C2-5; R32 es R33, C(O)R33, o C(O)OR33; R33 es R34 o R35; R34 es fenilo que no está fusionado o está fusionado con benceno, heteroareno, o R34A; R34A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R35 es alquilo que no está sustituido o está sustituido con R36; R36 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R36A; R36A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R37 es R38, R39 o R40, cada uno de los cuales está sustituido con F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(O)OR41, SR41, S(O)R41 o SO2R41; R38 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R38A; R38A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R39 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R39A; R39A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R40 es cicloalquilo C3-8 o cicloalquenilo C4-8, donde en cada uno una o dos porciones CH2 no se reemplazan o se reemplazan por sustituyentes seleccionados en forma independiente entre O, C(O), CNOH, CNOCH3, S, S(O), SO2 o NH y una o dos porciones CH no se reemplazan o
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34842210P | 2010-05-26 | 2010-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081552A1 true AR081552A1 (es) | 2012-10-03 |
Family
ID=45004346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101806 AR081552A1 (es) | 2010-05-26 | 2011-05-26 | Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes |
Country Status (39)
Country | Link |
---|---|
US (5) | US9006247B2 (es) |
EP (3) | EP3091017B1 (es) |
JP (1) | JP5782508B2 (es) |
KR (2) | KR101850679B1 (es) |
CN (2) | CN102939009B (es) |
AR (1) | AR081552A1 (es) |
AU (1) | AU2011258350B2 (es) |
BR (1) | BR112012029733B1 (es) |
CA (1) | CA2798765C (es) |
CL (1) | CL2012003285A1 (es) |
CO (1) | CO6640275A2 (es) |
CR (2) | CR20180222A (es) |
CY (1) | CY1117655T1 (es) |
DK (1) | DK2575463T3 (es) |
DO (3) | DOP2012000298A (es) |
EC (1) | ECSP12012348A (es) |
ES (2) | ES2666181T3 (es) |
GT (1) | GT201200315A (es) |
HK (1) | HK1182593A1 (es) |
HR (1) | HRP20160714T1 (es) |
HU (1) | HUE029231T2 (es) |
IL (2) | IL222831A (es) |
ME (1) | ME02452B (es) |
MX (1) | MX337104B (es) |
MY (1) | MY165427A (es) |
NZ (1) | NZ603284A (es) |
PE (2) | PE20130221A1 (es) |
PH (2) | PH12016501126A1 (es) |
PL (1) | PL2575463T3 (es) |
PT (1) | PT2575463T (es) |
RS (1) | RS54892B1 (es) |
RU (1) | RU2567857C2 (es) |
SG (3) | SG10201700112VA (es) |
SI (1) | SI2575463T1 (es) |
TW (1) | TWI520960B (es) |
UA (1) | UA109278C2 (es) |
UY (1) | UY33408A (es) |
WO (1) | WO2011150016A1 (es) |
ZA (1) | ZA201208727B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA2820618C (en) | 2010-11-23 | 2020-04-21 | Steven Elmore | Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
WO2014028381A1 (en) * | 2012-08-13 | 2014-02-20 | Abbvie Inc. | Apoptosis-inducing agents |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9539251B2 (en) | 2012-09-07 | 2017-01-10 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
BR122021025053B1 (pt) * | 2013-03-13 | 2022-09-06 | Abbvie Inc | Processo para a preparação de um agente indutor de apoptose |
AR095265A1 (es) | 2013-03-13 | 2015-09-30 | Abbvie Inc | Procesos para la preparación de un agente inductor de la apoptosis |
FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
NZ723035A (en) | 2014-01-28 | 2022-07-01 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US9238652B2 (en) | 2014-03-04 | 2016-01-19 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
EP3203840B1 (en) | 2014-10-06 | 2020-08-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
WO2017063572A1 (zh) * | 2015-10-13 | 2017-04-20 | 苏州晶云药物科技有限公司 | 细胞凋亡诱导剂的新晶型及其制备方法 |
CN106957315B (zh) * | 2016-01-08 | 2019-08-13 | 中国人民解放军第二军医大学 | N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途 |
AU2017240685B2 (en) | 2016-03-31 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20170300968A1 (en) * | 2016-04-14 | 2017-10-19 | Nb Portals, Llc | Method and system for disseminating information over a communication network |
RU2744358C2 (ru) | 2016-08-05 | 2021-03-05 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 |
CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
WO2018107100A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11053239B2 (en) | 2017-01-07 | 2021-07-06 | Fochon Pharmaceuticals, Ltd. | Compounds as BLC-2-selective apoptosis-inducing agents |
WO2018157803A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
CN108794358B (zh) * | 2017-04-27 | 2022-08-12 | 中国人民解放军第二军医大学 | 取代苯磺酰基类化合物及其制备药物的用途 |
BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
KR102606188B1 (ko) | 2017-08-02 | 2023-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 피롤리딘 화합물을 제조하기 위한 공정 |
CN107501260B (zh) * | 2017-08-14 | 2019-08-13 | 郑州大学第一附属医院 | 一种Bcl-2抑制剂venetoclax以及中间体的制备方法 |
ES2971457T3 (es) | 2017-08-23 | 2024-06-05 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de BCL-2 |
CN107445958A (zh) * | 2017-09-19 | 2017-12-08 | 上海泓博智源医药股份有限公司 | 一种abt‑199中间体的制备方法 |
AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
BR112020014169A2 (pt) | 2018-01-10 | 2020-12-08 | Recurium Ip Holdings, Llc | Compostos de benzamida |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US20190336496A1 (en) * | 2018-02-16 | 2019-11-07 | Abbvie Inc. | Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CA3098348A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 inhibitors |
KR20210003731A (ko) | 2018-07-31 | 2021-01-12 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도 |
KR20200139139A (ko) | 2018-07-31 | 2020-12-11 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과 |
CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
US11491167B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
CN112661751B (zh) * | 2019-10-16 | 2024-06-14 | 南京天印健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
WO2021231486A1 (en) * | 2020-05-13 | 2021-11-18 | Unity Biotechnology, Inc. | Cancer treatment by senescence induction followed by a senolytic |
CN114736203A (zh) * | 2021-01-07 | 2022-07-12 | 南京天印健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
EP4353722A1 (en) * | 2021-06-04 | 2024-04-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phosphate of trifluoromethyl-substituted sulfonamide compound |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
DE19830430A1 (de) * | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
ATE429423T1 (de) | 2004-07-20 | 2009-05-15 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
CN101534904B (zh) | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
RU2460725C2 (ru) | 2007-02-15 | 2012-09-10 | Ф. Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 |
US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
NZ601350A (en) | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP2376480B1 (en) * | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
MX2011007681A (es) * | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
KR101920202B1 (ko) * | 2009-05-26 | 2018-11-21 | 애브비 아일랜드 언리미티드 컴퍼니 | 암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
-
2011
- 2011-05-09 TW TW100116213A patent/TWI520960B/zh not_active IP Right Cessation
- 2011-05-25 SI SI201130872A patent/SI2575463T1/sl unknown
- 2011-05-25 CA CA2798765A patent/CA2798765C/en not_active Expired - Fee Related
- 2011-05-25 RS RS20160487A patent/RS54892B1/sr unknown
- 2011-05-25 PE PE2012002219A patent/PE20130221A1/es active IP Right Grant
- 2011-05-25 SG SG10201700112VA patent/SG10201700112VA/en unknown
- 2011-05-25 JP JP2013512188A patent/JP5782508B2/ja active Active
- 2011-05-25 WO PCT/US2011/037849 patent/WO2011150016A1/en active Application Filing
- 2011-05-25 EP EP16161558.8A patent/EP3091017B1/en active Active
- 2011-05-25 ES ES16161558.8T patent/ES2666181T3/es active Active
- 2011-05-25 UA UAA201214905A patent/UA109278C2/ru unknown
- 2011-05-25 CN CN201180025920.3A patent/CN102939009B/zh active Active
- 2011-05-25 SG SG2012081824A patent/SG185447A1/en unknown
- 2011-05-25 AU AU2011258350A patent/AU2011258350B2/en not_active Ceased
- 2011-05-25 NZ NZ603284A patent/NZ603284A/en not_active IP Right Cessation
- 2011-05-25 ME MEP-2016-126A patent/ME02452B/me unknown
- 2011-05-25 SG SG10201700115RA patent/SG10201700115RA/en unknown
- 2011-05-25 KR KR1020177018800A patent/KR101850679B1/ko active IP Right Grant
- 2011-05-25 PT PT117872994T patent/PT2575463T/pt unknown
- 2011-05-25 DK DK11787299.4T patent/DK2575463T3/en active
- 2011-05-25 CR CR20180222A patent/CR20180222A/es unknown
- 2011-05-25 EP EP11787299.4A patent/EP2575463B1/en active Active
- 2011-05-25 BR BR112012029733-3A patent/BR112012029733B1/pt not_active IP Right Cessation
- 2011-05-25 PL PL11787299.4T patent/PL2575463T3/pl unknown
- 2011-05-25 ES ES11787299.4T patent/ES2574855T3/es active Active
- 2011-05-25 PE PE2017000244A patent/PE20170465A1/es unknown
- 2011-05-25 EP EP17199100.3A patent/EP3312178A1/en not_active Withdrawn
- 2011-05-25 CN CN201510086898.3A patent/CN104961771B/zh active Active
- 2011-05-25 MY MYPI2012700921A patent/MY165427A/en unknown
- 2011-05-25 RU RU2012156940/04A patent/RU2567857C2/ru active
- 2011-05-25 HU HUE11787299A patent/HUE029231T2/en unknown
- 2011-05-25 US US13/115,376 patent/US9006247B2/en active Active
- 2011-05-25 MX MX2012013704A patent/MX337104B/es active IP Right Grant
- 2011-05-25 UY UY33408A patent/UY33408A/es not_active Application Discontinuation
- 2011-05-25 KR KR1020127033740A patent/KR101800167B1/ko active IP Right Grant
- 2011-05-26 AR ARP110101806 patent/AR081552A1/es active IP Right Grant
-
2012
- 2012-11-01 IL IL222831A patent/IL222831A/en active IP Right Grant
- 2012-11-20 ZA ZA2012/08727A patent/ZA201208727B/en unknown
- 2012-11-22 DO DO2012000298A patent/DOP2012000298A/es unknown
- 2012-11-23 GT GT201200315A patent/GT201200315A/es unknown
- 2012-11-23 CL CL2012003285A patent/CL2012003285A1/es unknown
- 2012-12-13 CO CO12226070A patent/CO6640275A2/es active IP Right Grant
- 2012-12-18 CR CR20120648A patent/CR20120648A/es unknown
- 2012-12-20 EC ECSP12012348 patent/ECSP12012348A/es unknown
-
2013
- 2013-08-27 HK HK13110018.2A patent/HK1182593A1/zh not_active IP Right Cessation
-
2014
- 2014-07-28 IL IL233832A patent/IL233832B/en active IP Right Grant
-
2015
- 2015-03-11 US US14/645,378 patent/US9403822B2/en active Active
-
2016
- 2016-05-04 DO DO2016000100A patent/DOP2016000100A/es unknown
- 2016-06-10 PH PH12016501126A patent/PH12016501126A1/en unknown
- 2016-06-15 CY CY20161100529T patent/CY1117655T1/el unknown
- 2016-06-21 HR HRP20160714TT patent/HRP20160714T1/hr unknown
- 2016-06-30 US US15/199,782 patent/US20170096424A1/en not_active Abandoned
-
2017
- 2017-08-09 DO DO2017000186A patent/DOP2017000186A/es unknown
-
2018
- 2018-06-13 PH PH12018501264A patent/PH12018501264A1/en unknown
- 2018-11-28 US US16/203,509 patent/US20190315737A1/en not_active Abandoned
-
2019
- 2019-10-24 US US16/663,285 patent/US20200277291A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081552A1 (es) | Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
AR076945A1 (es) | Agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
AR079124A1 (es) | Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
AR074510A1 (es) | Agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
AR076705A1 (es) | Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
AR076946A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
AR113918A1 (es) | Agentes antivirales contra la hepatitis b | |
CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
CY1122272T1 (el) | ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
AR089527A1 (es) | Inhibidores de bromodominios | |
AR091023A1 (es) | Inhibidores del nampt | |
PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
PE20220502A1 (es) | Compuestos utiles como inhibidores de cinasa | |
AR101177A1 (es) | Inhibidores de la syk | |
MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
PE20181272A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
JP2011132222A5 (es) | ||
AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
MY161233A (en) | Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds | |
AR075090A1 (es) | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |